重组人促红细胞生成素不良反应149例文献分析

Literature Analysis of Adverse Reactions Induced by Recombinant Human Erythropoietin in 149 Case Reports

目的:分析重组人促红细胞生成素(rHuEPO)药品不良反应(ADR)的发生情况,为临床安全用药提供参考。方法:收集国内外公开报道的rHuEPO的ADR文献资料,按患者年龄、性别、原患疾病、ADR发生时间、累及器官及临床表现、转归等进行整理并分析。结果:经检索,rHuEPO的ADR共计149例,累及器官主要有心血管系统损害(43.4%)、血液系统损害(20.8%)、皮肤及其附件损害(12.7%)。临床表现前3位分别是高血压、再生障碍性贫血、高钾血症。发生时间多集中在用药后5~12周内(43.0%)。结论:rHuEPO在临床使用过程中应关注其ADR、发生时间,注意患者用药教育及随访,避免严重ADR的发生。

Objective： To study the adverse reactions（ ADRs） of recombinant human erythropoietin（ rHuEPO） to provide reference for clinical rational and safe medication. Methods： ADRs induced by rHuEPO reported at home and abroad were collected and analyzed in respects of age,gender,original illness,occurrence time,clinical manifestations and the results. Results： After the retrieval,there were 149 cases of rHuEPO-induced ADRs with the damage of cardio vascular system,hematologic system,skin and its appendents accounting for 43. 4%,20. 8% and 12. 7%,respectively. The top three main clinical manifestations of rHuEPO drug reactions were hypertension,pure red-cell aplastic anemia（ PRCA） and hyperkalemia. The occurrence time should be paid particular attention in 5-12 weeks after the administration（ 43. 0%）. Conclusion： Physicians should be aware of rHuEPO-induced ADRs（ especially the occurrence time）,pay attention to patients＇ medication education and avoid serious adverse reactions.